Cost analysis of enhancing linkages to HIV care following jail: A cost-effective intervention

AIDS and Behavior

Volumn 17, Issue SUPPL. 2, 2013, Pages

  Spaulding, Anne C ^a   Pinkerton, Steven D ^b   Superak, Hillary ^a   Cunningham, Marc J ^a   Resch, Stephen ^c   Jordan, Alison O ^d   Yang, Zhou ^a  

^a EMORY UNIVERSITY   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ADULT; COMMUNITY CARE; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH CARE COST; HIV INFECTIONS; HUMAN; MALE; MIDDLE AGED; PRISON; PROGRAM EVALUATION; QUALITY ADJUSTED LIFE YEAR; SOCIAL SUPPORT; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UNITED STATES; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; STATISTICS;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; COMMUNITY HEALTH SERVICES; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PRISONS; PROGRAM EVALUATION; QUALITY-ADJUSTED LIFE YEARS; SOCIAL SUPPORT; UNITED STATES;

EID: 84892787455     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-012-0353-4     Document Type: Article

References (23)

1. Spaulding AC, Seals RM, Page MJ, Brzozowski AK, Rhodes W, Hammett TM. HIV/AIDS among inmates of, and releasees from, US correctional facilities, 2006 declining share of epidemic but persistent public health opportunity. PLoS One. 2009;4(11):e7558. doi:10.1371/journal.pone.0007558.
2. Westergaard RP, Kirk GD, Richesson DR, Galai N, Mehta SH. Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy. Clin Infect Dis. 2011;53(7):725-31.
3. National HIV/AIDS strategy for the United States. 2010. http://www.whitehouse.gov/sites/default/files/uploads/NHAS.pdf. Accessed 3 Dec 2010.
4. Shrestha RK, Sansom SL, Richardson-Moore A, et al. Costs of voluntary rapid HIV testing and counseling in jails in 4 states advancing HIV prevention demonstration project 2003-2006. Sex Transm Dis. 2009;36(Suppl 2):S5-8.
5. Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: Implications for HIV prevention programs. J Acquir Immune Defic Syndr: JAIDS. 2005;39(4):446-53.
6. Holtgrave DR, Hall HI, Rhodes PH, Wolitski RJ. Updated annual HIV transmission rates in the United States, 1977-2006 (Letter to the editor). J Acquir Immune Defic Syndr. 2009;50:236-8.
7. Draine J, Ahuja D, Altice FL, et al. Strategies to enhance linkages between care for HIV/AIDS in jail and community settings. AIDS Care. 2011;23(3):366-77.
8. Pinkerton S. HIV Transmission rate modeling: A primer, review, and extension. AIDS Behav. 2012;16(4):791-6.
9. Centers for Disease Control and Prevention. HIV surveillance - United States, 1981-2008. MMWR. 2011;60:689-93.
10. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006-2009. PLoS One. 2011;6(8):e17502.
11. Gardner LI, Metsch LR, Anderson-Mahoney P, et al. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS. 2005;19(4):423-31.
12. Hutchinson AB, Farnham PG, Dean HD, Ekwueme DU, del Rio C, Kamimoto L. The economic burden of HIV in the US in the era of highly active antiretroviral therapy: Evidence of continuing racial and ethnic differences. JAIDS. 2006;43(4):451-7.
13. Gebo KA, Fleishman JA, Conviser R, et al. Contemporary costs of HIV healthcare in the HAART era. AIDS. 2010;24(17): 2705-15.
14. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44(11):990-7.
15. Farnham PG, Sansom SL, Hutchinson AB. How much should we pay for a new HIV diagnosis A mathematical model of HIV screening in US clinical settings. Méd Decis Mak. 2012;32(3): 459-69.
16. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505.
17. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type N Engl J Med. 2000;342(13):921-9.
18. Centers for disease control and prevention. HIV cost-effectiveness. 2012. http://www.cdc.gov/hiv/topics/preventionporgrams/ce/index.htm. Accessed 15 Jun 2012.
19. CDC'S new high-impact approach to HIV prevention funding for health departments advancing the national HIV/AIDS strategy. Fact sheet. 2011. http://www.cdc.gov/hiv/topics/funding/PS12-1201/resources/factsheet/pdf/ foa-partner.pdf. Accessed 5 Sept 2011.
20. NIH, office of AIDS research. Translating research from bench to bedside to community. 2010. http://www.oar.nih.gov/strategicplan /fy2011/pdf/ FY2011ByPassPlan-08-Plan.pdf in FY Trans-NIH Plan for HIV-related research, available at: Http://www.oar.nih.gov /strategicplan/fy2011/index.asp. Accessed 6 Mar 2010.
21. Cohen SM, van Handel MM, Branson BM, et al. Vital Signs: HIV prevention through care and treatment - United States MMWR. 2011;60(47):1618-23.
22. Pinkerton SD. How many sexually-acquired HIV infections in the USA are due to acute phase HIV transmission AIDS. 2007;21: 1625-29.
23. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they infected with the virus in the USA. AIDS. Jun 26 2006;20(10):1447-50